KRAS and non-small cell lung carcinoma: In conclusion, this study provides a strong rationale for the clinical evaluation of anlotinib in combination with KRAS-G12C inhibitors in NSCLC patients with primary or acquired resistance to KRAS-G12Ci monotherapy.